ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BTX Brooklyn ImmunoTherapeutics Inc

9.79
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Brooklyn ImmunoTherapeutics Inc AMEX:BTX AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.79 0 01:00:00

Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts

15/09/2021 1:15pm

PR Newswire (US)


Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Brooklyn ImmunoTherapeut... Charts.

CAMBRIDGE, Mass., Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, Massachusetts, celebrated its tenth anniversary on September 9, 2021 with the grand opening of its new ISO Class 7 cleanroom facility at its headquarters near Inman Square. The new facility allows Factor and its strategic partners to produce advanced mRNA, gene-editing, and cell-therapy products for all phases of clinical development.

Pictured from left to right: Howard Federoff, M.D., Ph.D., CEO of Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX); Christopher Rohde, Ph.D., Co-Founder and Chief Technology Officer of Factor Bioscience Inc.; Gregory Fiore, M.D., Co-Founder and CEO of Exacis Biotherapeutics Inc.; Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc.

"This expansion will accelerate the development of important therapeutic applications of our technologies in areas such as anti-inflammatory, anti-cancer, and regenerative medicine," said Factor Co-Founder, Chairman, and CEO, Matt Angel, Ph.D. "This is the culmination of a decade of work by the Factor team and a shared vision between us and our strategic partners."

Dr. Angel was joined by leadership representatives from those partners in a formal ribbon cutting ceremony. In addition to Factor Co-Founder and Chief Technology Officer Christopher Rohde, Ph.D., Gregory Fiore, M.D., Co-Founder and CEO of Exacis Biotherapeutics Inc., and Howard Federoff, M.D., Ph.D., CEO of Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) helped dedicate the new facility.

"We are excited to announce this major step forward," said Dr. Fiore. "Securing a dedicated GMP manufacturing capacity within the Factor facility allows us to produce our unique and high-quality cells on our own timeline as we progress toward the clinic."

"The new mRNA cleanroom facility is an important part of our planned R&D operations, and of strategic advantage as we share the space with Factor Bioscience, from which we have in-licensed critical mRNA gene editing technology," said Dr. Federoff.

About Factor Bioscience
Founded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. Factor Bioscience is privately held and is headquartered in Cambridge, MA. For more information, visit www.factorbio.com.

Media Contact:
Allen Mireles
allen.mireles@scistories.com

Factor Bioscience Inc. (PRNewsfoto/Factor Bioscience Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/factor-bioscience-celebrates-10th-anniversary-with-grand-opening-of-iso-class-7-cleanroom-facility-in-cambridge-massachusetts-301377011.html

SOURCE Factor Bioscience

Copyright 2021 PR Newswire

1 Year Brooklyn ImmunoTherapeut... Chart

1 Year Brooklyn ImmunoTherapeut... Chart

1 Month Brooklyn ImmunoTherapeut... Chart

1 Month Brooklyn ImmunoTherapeut... Chart

Your Recent History

Delayed Upgrade Clock